KDM6B and osteosarcoma: In osteosarcoma, elevated JMJD3 levels correlate with cisplatin resistance, and inhibiting JMJD3 restores tumor sensitivity to cisplatin by inactivating the RAF/ERK/MAPK pathway and silencing protein kinase C alpha and myeloid cell leukemia 1 [136].